<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00014300</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-16994G-26002</org_study_id>
    <secondary_id>EORTC-16994G-26002</secondary_id>
    <nct_id>NCT00014300</nct_id>
  </id_info>
  <brief_title>Glufosfamide in Treating Patients With Recurrent Glioblastoma Multiforme</brief_title>
  <official_title>Open Label Phase II Study On Glufosfamide Administered As A 60 Minute Infusion Every 3 Weeks In Recurrent Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die.

      PURPOSE: Phase II trial to study the effectiveness of glufosfamide in treating patients who
      have recurrent glioblastoma multiforme.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the activity of glufosfamide, in terms of objective response rate
      and/or progression-free survival at 6 months, in patients with recurrent glioblastoma
      multiforme. II. Determine the duration of objective response in patients treated with this
      regimen. III. Determine the toxic effects and pharmacokinetic profile of this regimen in
      these patients.

      OUTLINE: This is a multicenter study. Patients receive glufosfamide IV over 60 minutes on day
      1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable
      toxicity. Patients with stable disease receive treatment for a minimum of 6 months or until
      progression. Patients with an objective complete response receive a maximum of 2 additional
      courses of treatment after confirmation of response. Patients are followed every 6 weeks
      until progression.

      PROJECTED ACCRUAL: A total of 28 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2001</start_date>
  <primary_completion_date type="Actual">September 2001</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">32</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glufosfamide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically or cytologically confirmed glioblastoma multiforme
        Recurrent disease by CT scan or MRI At least 1 bidimensionally measurable target lesion at
        least 2 cm in the largest diameter

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At
        least 3 months Hematopoietic: Neutrophil count at least 1,500/mm3 Platelet count at least
        100,000/mm3 Hepatic: Bilirubin less than 1.5 times upper limit of normal (ULN) Alkaline
        phosphatase no greater than 2.5 times ULN AST and ALT no greater than 2.5 times ULN Renal:
        Creatinine no greater than 1.5 mg/dL Creatinine clearance at least 60 mL/min
        Cardiovascular: Cardiac function normal No history of ischemic heart disease within the
        past 6 months 12 lead ECG normal Other: No other prior or concurrent malignancy except cone
        biopsied cervical cancer or adequately treated basal cell or squamous cell skin cancer No
        unstable systemic disease No active uncontrolled infection No psychological, familial,
        sociological, or geographical condition that would preclude study Not pregnant or nursing
        Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent prophylactic growth factors
        (e.g., filgrastim (G-CSF)) Chemotherapy: No more than 1 prior chemotherapy regimen as
        adjuvant therapy or for recurrent disease At least 6 weeks since prior chemotherapy
        Endocrine therapy: Stable or decreasing dose of corticosteroids for at least 1 week prior
        to study Radiotherapy: At least 3 months since prior radiotherapy to the brain No prior
        high-dose radiotherapy (more than 65 Gy), stereotactic radiosurgery, or internal
        radiotherapy unless the disease recurrence is histologically confirmed Surgery: No prior
        surgery (except biopsy) for recurrent brain tumor At least 3 months since prior surgery for
        primary brain tumor Other: No other concurrent anticancer agents No other concurrent
        investigational agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin J. van Den Bent, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Daniel Den Hoed Cancer Center at Erasmus Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaiser Franz Josef Hospital</name>
      <address>
        <city>Vienna (Wien)</city>
        <zip>A-1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Lute Contre le Cancer,Georges-Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRLCC Nantes - Atlantique</name>
      <address>
        <city>Nantes-Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Pitie-Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35064</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>F-94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ioannina</name>
      <address>
        <city>Ioannina</city>
        <zip>GR-45110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schneider Children's Medical Center of Israel</name>
      <address>
        <city>Petah-Tikva</city>
        <zip>49202</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova (Padua)</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituti Fisioterapici Ospitalieri - Roma</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rotterdam Cancer Institute</name>
      <address>
        <city>Rotterdam</city>
        <zip>3075 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3508 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Portugues de Oncologia de Francisco Gentil</name>
      <address>
        <city>Lisbon</city>
        <zip>1093</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital - St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2001</study_first_submitted>
  <study_first_submitted_qc>March 16, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2004</study_first_posted>
  <last_update_submitted>September 20, 2012</last_update_submitted>
  <last_update_submitted_qc>September 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

